From: Data-driven FDG-PET subtypes of Alzheimer’s disease-related neurodegeneration
Prodromal AD group, no hypometabolism (S0) | Prodromal AD group, limbic-predominant (S1) | Prodromal AD group, typical (S2) | P value, global comparison (S0, S1 and S2) | Pair-wise comparisons | |||
---|---|---|---|---|---|---|---|
S0 vs S1 | S0 vs S2 | S1 vs S2 | |||||
Demographics | |||||||
n (%) | 57 (26.3%) | 108 (49.8%) | 49 (22.6%) | ||||
Age, years | 68.4 (6.6) | 76.1 (5.7) | 71.7 (6.2) | < 0.001 | < 0.001 | 0.009 | < 0.001 |
Sex, female (%) | 60% | 35% | 41% | 0.01 | 0.024 | 0.226 | 1 |
Education, years | 16.2 (2.8) | 15.7 (3.0) | 16.4 (2.6) | 0.344 | |||
Cognition | |||||||
MMSE | 28.2 (1.8) | 27.6 (1.8) | 27.3 (1.8) | 0.053 | |||
ADNI-MEM | 0.57 (0.63) | 0.05 (0.61) | − 0.06 (0.65) | < 0.001 | < 0.001 | < 0.001 | 0.602 |
ADNI-EF | 0.76 (0.91) | 0.00 (0.77) | 0.15 (1.01) | 0.018 | < 0.001 | 0.001 | 0.542 |
ADNI-DIFF | − 0.19 (0.83) | 0.05 (0.78) | − 0.21 (0.77) | 0.616 | |||
ADNI-VS | 0.08 (0.65) | − 0.06 (0.76) | − 0.21 (0.67) | 0.135 | |||
ADNI-Lan | 0.6 (0.7) | − 0.05 (0.74) | 0.29 (0.79) | 0.007 | < 0.001 | 0.062 | 0.025 |
Biomarkers | |||||||
APOE ε4 (%) | 68% | 62% | 77% | 0.163 | |||
AV45-PET SUVR | 1.31 (0.17) | 1.39 (0.17) | 1.43 (0.15) | 0.004 | 0.015 | 0.002 | 0.238 |
CSF Aβ, pg/ml | 921 (437) | 736 (237) | 672 (214) | 0.002 | < 0.001 | < 0.001 | 0.417 |
CSF t-tau, pg/ml | 315 (134) | 337 (137) | 357 (144) | 0.123 | |||
CSF p-tau, pg/ml | 31 (15) | 34 (16) | 37 (16) | 0.096 | |||
HV | 4.86 (0.45) | 4.53 (0.51) | 4.57 (0.41) | 0.009 | < 0.001 | 0.005 | 1 |
CTV | 89.87 (5.45) | 83.19 (6.48) | 82.93 (5.35) | < 0.001 | < 0.001 | < 0.001 | 1 |
HV:CTV ratio | 54.26 (6.07) | 54.57 (6.27) | 55.24 (5.56) | 0.344 | |||
WMH | 4.9 (5.0) | 11.3 (12.8) | 6.8 (6.5) | 0.172 |